Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Apr;14(4):809-811.
doi: 10.21037/jtd-22-57.

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer

Tatsuya Nagano  1 , Motoko Tachihara  1 , Yugo Tanaka  2
Affiliations
Editorial

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer

Tatsuya Nagano et al. J Thorac Dis. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-57/coif). MT reports grants and personal fees from AstraZeneca, personal fees from Chugai, personal fees from Boehringer ingelheim, personal fees from Pfizer, during the conduct of the study; grants and personal fees from AstraZeneca, personal fees from Chugai, personal fees from Boehringer ingelheim, personal fees from Pfizer, outside the submitted work. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Wu YL, John T, Grohe C, et al. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol 2022;17:423-33. 10.1016/j.jtho.2021.10.014 - DOI - PubMed
    1. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020;383:1711-23. 10.1056/NEJMoa2027071 - DOI - PubMed
    1. Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells 2018;7:212. 10.3390/cells7110212 - DOI - PMC - PubMed
    1. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629-40. 10.1056/NEJMoa1612674 - DOI - PMC - PubMed
    1. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382:41-50. 10.1056/NEJMoa1913662 - DOI - PubMed